Premium
The arterial wall: a new pharmacological and therapeutic target *
Author(s) -
Laurent S.,
Vanhoutte P.,
Cavero I.,
Chabrier PE,
Dupuis B.,
Elghozi JL,
Hamon G.,
Janiak P.,
Juillet Y.,
Kher A.,
Koen R.,
Madonna O.,
Maffrand JP,
Pruneau D.,
Thuillez C.
Publication year - 1996
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1996.tb00303.x
Subject(s) - restenosis , endothelin receptor , receptor , medicine , vascular smooth muscle , endothelial dysfunction , vascular remodelling in the embryo , pharmacology , endothelium , angiotensin ii , smooth muscle , endothelins , angiotensin converting enzyme , cardiology , biology , blood pressure , stent
Summary— In recent years, two key concepts having numerous interrelationships were advanced for the understanding of various cardiovascular diseases: the “endothelial dysfunction” and the “arterial remodelling”. Both endothelial dysfunction and arterial remodelling occur in various pathologies including essential hypertension, heart failure, atherosclerosis, restenosis after angioplasty, and pulmonary hypertension, and have modified the therapeutic approach by offering new pharmacological targets: specific receptors not only at the site of the vascular smooth muscle cells but also on the endothelial cells, growth factors that stimulate proliferation of smooth muscle, and receptors and enzymes of the extra‐cellular matrix. Among the various substances under research, the present review will discuss angiotensin II receptor antagonists, endothelin receptor antagonists, nitrates‐NO donors, potassium channel activators, and substances interfering with proteoglycans and other components of the extra‐cellular matrix.